Winning Stock Forecast: PTN Stock Headed For The Top?

Palatin Technologies, Inc. (NYSE: PTN) is a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems.

On May 12th 2019, Know First issued a bullish 1-month forecast for Palatin Technologies, Inc. (NYSE: PTN). The forecast illustrated a signal of 8.25 and a predictability of 0.35. In good agreement with the forecast, PTN was the highest-earning trade with a return of 27.59% in 1 Month in I Know First’s suggested trades in the Stocks Under 5 Dollars Package for this 1 Month forecast, highlighting the accuracy of the prediction produced by the I Know First algorithm.

Another Leap

Palatin Technologies has many programs under their wing, such as their Anti-Inflammatory / Autoimmune Programs, Natriuretic Peptide Receptor (“NPR”) System Program and the Genetic obesity program. Their greatest focus now is on their lead product, Vyleesi, the trade name for Bremelanotide, for the treatment of hypoactive sexual desire disorder (HSDD).  

Vyleesi is given by subcutaneous injection under the skin using a single use autoinjector pen.  There is no visible needle with the autoinjector. Vyleesi is used only as needed prior to anticipated sexual activity.  Women will not have to take Vyleesi on a daily basis.

Currently, a New Drug Application for approval of Vyleesi is pending before the Food and Drug Administration (FDA).The PDUFA (Prescription Drug User Fee Act) goal date for completion of FDA review of the Vyleesi New Drug Application is June 23, 2019.

In Good Hands

PTN stock has been a good ray of sunshine among the clouds. The stock climbed from $1.15 on 12th April to $1.5 on 14th May. Perhaps their rise could be attributed to the fairly substantial increase in institutional ownership from around 10% to slightly over 20% in early 2019. Some new institutional owners are notable investment management firms, such as BlackRock Inc. and Acadian Asset Management LLC. Considering the vast amount of resources, talent, and research capacity these large money managers have at their disposal, their investment in PTN is likely to aid and improve Palatin’s business, giving rise to a positive crowd sentiment as well.

[Nasdaq]

When The Body Is Healthy, Everything Else Is

Debt and related liabilities reduced from $7.2 million at June 30, 2018 to $1.8 million at March 31, 2019. Palatin Technologies, Inc. (PTN)’s current-quarter revenues are projected to increase to $60.01 million, based on current Zacks Consensus Estimate. Total operating expenses for the quarter ended March 31, 2019 were $5.8 million compared to $9.5 million for the comparable quarter in 2018.  The decrease in operating expenses was mainly due to the completion of the Vyleesi Phase 3 clinical trial program and ancillary studies necessary to file the NDA for Vyleesi in March 2018.

Palatin’s cash and cash equivalents were $19.8 million as of March 31, 2019, compared to cash and cash equivalents of $38.0 million at June 30, 2018.  Current liabilities were $4.9 million as of March 31, 2019, compared to $10.8 million as of June 30, 2018. Palatin believes that existing capital resources will be sufficient to fund planned operations through at least May 31, 2020.

On May 12th 2019, Know First issued a bullish 1-month forecast for Palatin Technologies, Inc. (NYSE: PTN). The forecast illustrated a signal of 8.25 and a predictability of 0.35. In good agreement with the forecast, PTN was the highest-earning trade with a return of 27.59% in 1 Month in I Know First’s suggested trades in the Stocks Under 5 Dollars Package for this 1 Month forecast, highlighting the accuracy of the prediction produced by the I Know First algorithm. Due to an impending FDA product approval, good financial health of the company and the increase in institutional ownership, we can expect the PTN stock to continue growing.


How to interpret this diagram

Current I Know First subscribers received a bullish PTN forecast on 12th April with a signal of 8.25 with a predictability score of 0.35 for a month-long time frame. Algorithmic traders utilize these daily forecasts by the I Know First market prediction system as a tool to enhance portfolio performance, verify their own analysis and act on market opportunities faster. This forecast was sent to current I Know First subscribers.

Algorithmic traders utilize these daily forecasts by the I Know First market prediction system as a tool to enhance portfolio performance, verify their own analysis and act on market opportunities faster. This forecast was sent to current I Know First subscribers.

Please note-for trading decisions use the most recent forecast.

 Get today’s forecast and Top stock picks.